Table 3. Risk factors for 14-day mortality (n = 276).
| Characteristics | Survival (n = 253) | Mortality (n = 23) | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|---|
| OR | P | OR | P | ||||
| Age (mean, SD) | 57.1, 14.1 | 59.8, 13.7 | - | 0.35 | |||
| Male gender (%) | 152 (60.0) | 14 (60.9) | 1.03 (0.43, 2.48) | 1.00 | |||
| Type of cancer | |||||||
| Solid tumors (%) | 143 (56.5) | 10 (43.5) | 0.59 (0.25, 1.40) | 0.28 | |||
| Hematologic malignancies (%) | 117 (46.2) | 15 (65.2) | 2.18 (0.89, 5.32) | 0.09 | 5.45 | 0.01 | |
| ESBL (%) | 41 (16.2) | 8 (34.8) | 2.76 (1.10, 6.93) | 0.04 | 3.89 | 0.01 | |
| Comorbidities | |||||||
| DM (%) | 67 (26.5) | 9 (39.1) | 1.79 (0.74, 4.31) | 0.22 | |||
| Chronic liver disease (%) | 17 (6.7) | 4 (17.4) | 2.92 (0.89, 9.56) | 0.08 | |||
| Hematopoietic stem cell transplant (%) | 18 (7.1) | 1 (4.3) | 0.59 (0.08, 4.66) | 1.00 | |||
| Cardiovascular disease (%) | 15 (5.9) | 2 (8.7) | 1.51 (0.32, 7.06) | 0.64 | |||
| Chronic renal disease (%) | 4 (1.6) | 1 (4.3) | 2.83 (0.30, 26.43) | 0.36 | |||
| Neurologic disease (%) | 3 (1.2) | 1 (4.3) | 3.79 (0.38, 37.96) | 0.30 | |||
| Chronic pulmonary disease (%) | 2 (0.8) | 0 (0.0) | N/A | N/A | |||
| Rapidly fatal disease (%) | 71 (28.1) | 8 (34.8) | 1.37 (0.56, 3.37) | 0.48 | |||
| Charlson score (mean, SD) | 4.99, 2.40 | 4.96, 2.90 | N/A | 0.98 | 1.29 | 0.04 | |
| Risk factors | |||||||
| Neutropenia (%) | 129 (51.0) | 15 (65.2) | 1.80 (0.74, 4.40) | 0.28 | |||
| Corticosteroid use (%) | 5 (2.0) | 2 (8.7) | 4.72 (0.86, 25.84) | 0.11 | |||
| Immunosuppressant use (%) | 24 (9.5) | 1 (4.3) | 0.43 (0.06, 3.36) | 0.71 | |||
| Foley catheter (%) | 56 (22.1) | 8 (34.8) | 1.88 (0.76, 4.65) | 0.20 | |||
| Central venous catheter (%) | 133 (52.6) | 12 (52.2) | 0.98 (0.42, 2.31) | 1.00 | |||
| Percutaneous drainage catheter (%) | 23 (9.1) | 4 (17.4) | 2.11 (0.66, 6.72) | 0.26 | |||
| Nasogastric tube (%) | 10 (4.0) | 2 (8.7) | 2.31 (0.48, 11.26) | 0.26 | |||
| Invasive procedure within 7 d (%) | 24 (9.5) | 3 (13.0) | 1.43 (0.40, 5.17) | 0.48 | |||
| Surgery within 90 d (%) | 29 (11.5) | 3 (13.0) | 1.16 (0.32, 4.14) | 0.74 | |||
| Mechanical ventilation (%) | 4 (1.6) | 2 (8.7) | 5.93 (1.03, 34.28) | 0.08 | |||
| Hemodialysis (%) | 2 (0.8) | 3 (13.0) | 18.83 (2.97, 119.27) | 0.005 | 10.10 | 0.03 | |
| Hospital-acquired infection (%) | 137 (5.4) | 11 (47.8) | 0.78 (0.33, 1.82) | 0.67 | |||
| Type of infection | |||||||
| Primary bacteremia (%) | 90 (35.6) | 5 (21.7) | 0.50 (0.18, 1.40) | 0.25 | |||
| Catheter-related (%) | 15 (5.9) | 5 (21.7) | 4.41 (1.44, 13.51) | 0.02 | |||
| Urinary tract (%) | 31 (12.3) | 6 (26.1) | 2.53 (0.93, 6.90) | 0.10 | |||
| Pancreatobiliary (%) | 43 (17.0) | 3 (13.0) | 0.73 (0.21, 2.58) | 0.78 | |||
| Intraabdominal (%) | 51 (20.2) | 2 (8.7) | 0.38 (0.09, 1.67) | 0.27 | |||
| Respiratory (%) | 33 (13.0) | 4 (17.4) | 1.40 (0.45, 4.38) | 0.53 | |||
| Skin & soft tissue (%) | 15 (5.9) | 3 (13.0) | 2.38 (0.64, 8.92) | 0.18 | |||
| Others (%) | 2 (0.8) | 1 (4.3) | 5.71 (0.50, 65.43) | 0.23 | |||
| Severity of infection | |||||||
| Pitt bacteremia score (mean, SD) | 1.56, 1.58 | 3.43, 3.04 | N/A | 0.001 | 1.57 | <0.001 | |
| Empirical antibiotic therapy | |||||||
| Inappropriate empirical therapy (%) | 26 (10.3) | 5 (21.7) | 2.43 (0.83, 7.08) | 0.16 | |||
| Piperacillin-tazobactam (%) | 53 (20.9) | 3 (13.0) | 0.57 (0.16, 1.98) | 0.59 | |||
| Third-generation cephalosporins (%) | 49 (19.4) | 3 (13.0) | 0.62 (0.18, 2.19) | 0.59 | |||
| Fourth-generation cephalosporins (%) | 78 (30.8) | 4 (17.4) | 0.47 (0.16, 1.43) | 0.24 | |||
| Aminoglycosides (%) | 0 (0.0) | 1 (4.3) | N/A | N/A | |||
| Fluoroquinolones (%) | 26 (10.3) | 3 (13.0) | 1.31 (0.36, 4.71) | 0.72 | |||
| Carbapenems (%) | 76 (30.0) | 13 (56.5) | 3.03 (1.27,7.21) | 0.02 | |||
| Vancomycin (%) | 34 (13.4) | 7 (30.4) | 2.82 (1.08, 7.35) | 0.06 | |||
| Definitive antibiotic therapy (n = 112) | |||||||
| Duration before modification (d; mean, SD) | 4.06, 1.08 | 3.78, 0.97 | N/A | 0.46 | |||
| Inappropriate definite therapy (%) | 1 (0.4) | 0 (0.0) | N/A | N/A | |||
| Piperacillin-tazobactam (%) | 3 (1.2) | 1 (4.3) | 4.17 (0.39, 44.8) | 0.29 | |||
| Third-generation cephalosporins (%) | 24 (9.5) | 1 (4.3) | 0.41 (0.05, 3.46) | 0.68 | |||
| Fourth-generation cephalosporins (%) | 21 (8.3) | 1 (4.3) | 0.49 (0.06, 4.12) | 0.69 | |||
| Aminoglycosides (%) | 0 (0.0) | 1 (4.3) | N/A | N/A | |||
| Fluoroquinolones (%) | 19 (7.5) | 0 (0.0) | N/A | N/A | |||
| Carbapenems (%) | 27 (10.7) | 3 (13.0) | 1.41 (0.33, 6.02) | 0.70 | |||
| Vancomycin (%) | 1 (0.4) | 1 (4.3) | 12.75 (0.73, 223.46) | 0.16 | |||
OR, odds ratio; SD, standard deviation; N/A, not applicable; ESBL, extended-spectrum beta-lactamase; DM, diabetes mellitus; d, days.